Christopher Adams
Chief Executive Officer Andarix Pharmaceuticals.
Seminars
Wednesday 22nd July 2026
From Imaging to Therapeutic Impact: Unlocking the Clinical Potential of Astatine-211 Alpha Radioligand Therapy
12:00 pm
- Translating α-emission into clinically meaningful tumor control for metastases
- Overcoming production, stability, and in vivo deastatination challenges to enable reliable imaging, dosimetry, and therapy
- Optimizing dose delivery, safety, and realworld scalability
